Celularity (NASDAQ:CELU) Rating Lowered to “Sell” at Wall Street Zen

Celularity (NASDAQ:CELU) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

Separately, WBB Securities started coverage on shares of Celularity in a research report on Monday, August 18th. They set a “moderate buy” rating and a $6.00 target price for the company.

Celularity Price Performance

Shares of CELU opened at $2.41 on Friday. The firm has a market capitalization of $57.72 million, a PE ratio of -0.76 and a beta of 0.81. The company has a debt-to-equity ratio of 4.07, a current ratio of 0.25 and a quick ratio of 0.28. Celularity has a 1-year low of $1.00 and a 1-year high of $5.22. The company’s fifty day moving average price is $3.00 and its 200-day moving average price is $2.17.

Celularity (NASDAQ:CELU) last announced its quarterly earnings data on Friday, August 29th. The company reported ($1.02) earnings per share for the quarter. The company had revenue of $5.74 million for the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 35,647.70%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd raised its position in shares of Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after acquiring an additional 11,057 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Celularity in the first quarter worth about $34,000. Bank of America Corp DE raised its position in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after acquiring an additional 35,023 shares during the period. Two Sigma Investments LP acquired a new position in shares of Celularity in the fourth quarter worth about $93,000. Finally, Valmark Advisers Inc. acquired a new position in shares of Celularity in the second quarter worth about $98,000. Institutional investors and hedge funds own 19.02% of the company’s stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.